Journal of the Egyptian National Cancer Institute

Table 2 Overall survival and its relation to different prognostic factors

From: Outcome and prognostic factors of pediatric patients with Hodgkin lymphoma: a single-center experience

Factors		OS %				Median (months)
Factors	n	6 m	1 yr	2 yrs	3 yrs	95% CI	p-value
All	69	98.6	95.5	91.9	91.9	NA	NA
Gender
Male	57	98.2	96.4	92.2	92.2	53.4 (31.4–75.5)	0.895
Female	12	100	90.9	90.9	90.9	NA
Age groups
0–5 yrs	13	100	92.3	92.3	92.3	NA	0.038
> 5–10 yrs	29	96.6	92.8	92.8	92.8	55.2
> 10–15 yrs	21	100	100	100	100	53.5
≥ 15 yrs	6	100	100	40.0	40.0	23.4 (8.4–38.5)
ESR
< 30	44	97.7	92.8	92.8	92.8	55.2	0.524
≥ 30	25	100	100	90.4	90.4	53.4
LN no
< 3	40	100	100	100	100	NA	0.008
≥ 3	29	96.6	89.4	81.3	81.3	55.0
Extra nodal
No	37	100	100	100	100	NA	0.017
Yes	32	96.9	90.6	83.3	83.3	NA
Liver involvement
No	62	98.4	96.7	94.3	94.3	55.2	0.008
Yes	7	100	85.7	71.4	71.4	53.4
Bone marrow involvement
No	62	98.4	96.7	92.6	92.6	55.2	0.350
Yes	7	100	85.7	85.7	85.7	53.5
Lung involvement
No	63	100	98.3	96.7	96.7	55.2	< 0.001
Yes	6	83.3	66.7	33.3	NA	23.4 (6.5–40.2)
Bulky disease
No	56	98.2	98.2	93.6	93.6	55.2	0.245
Yes	13	100	84.6	84.6	84.6	NA
Stage
I–II	33	100	100	100	100	NA	0.032
III–IV	36	97.2	91.5	85.0	85.0	NA
B symptoms
No	45	100	97.6	97.6	97.6	55.2	0.033
Yes	24	95.8	91.7	81.7	81.7	NA
CMT
No	47	97.9	93.3	89.9	89.9	NA	0.720
Yes	22	100	100	95.5	95.5	53.4 (24.1–82.7)
Histopathology subtypes
MC	29	100	96.4	96.4	96.4	NA	0.258
NS	36	97.2	94.3	87.5	87.5	55.2
Radiotherapy dose
15	15	100	93.3	93.3	93.3	53.4	0.495
20	7	100	100	100	100	NA
Interim PET-CT
Negative	60	100	96.5	94.7	94.7	55.2	0.068
Positive	9	88.9	88.9	88.9	74.1	NA
Interim negative & CMT
No	43	100	95	95	95	100–100	0.35
Yes	17	100	100	100	100	88.4–100

CMT combined modality treatment, MC mixed cellularity, NS nodular sclerosis, ESR erythrocyte sedimentation rate, LN lymph node, PET-CT positron emission tomography-computed tomography

Back to article page